buformin has been researched along with Acute Lung Injury in 1 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
Acute Lung Injury: A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, B | 1 |
| Wang, Z | 1 |
| He, R | 1 |
| Xiong, R | 1 |
| Li, G | 1 |
| Zhang, L | 1 |
| Fu, T | 1 |
| Li, C | 1 |
| Li, N | 1 |
| Geng, Q | 1 |
1 other study available for buformin and Acute Lung Injury
| Article | Year |
|---|---|
Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway.
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Animals; Autophagy; Buformin; Cell Line; Drug Eval | 2022 |